Core Insights - The stock of Innovent Biologics-B (09939) was transferred from Futu Securities International Hong Kong to Adept Securities Futures on October 15, with a market value of HKD 64.43 million, representing 6.49% of the total shares [1] Company Developments - Innovent Biologics-B has completed the enrollment of 130 participants in the long-term safety trial for its self-developed tyrosinase inhibitor KT-939, which effectively inhibits melanin production [1] - KT-939 precisely targets tyrosinase, efficiently blocking the oxidation process of tyrosine, thereby effectively curbing melanin production while also possessing antioxidant and anti-inflammatory properties [1] - The product demonstrates significant advantages in both efficacy and safety for cosmetic applications [1]
开拓药业-B股东将股票由富途证券国际香港转入艾德证券期货 转仓市值6443.21万港元